Total trials
353
Active
3
Phase 3
149
Total enrollment
81,712
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Replagal | — | — | — | 5 |
Next readouts
- 2026-10-31
Top conditions
- Hereditary Angioedema (HAE)26
- Healthy20
- Short Bowel Syndrome15
- Attention Deficit Hyperactivity Disorder (ADHD)15
- Ulcerative Colitis13
- Hunter Syndrome12
- Hereditary Angioedema12
- Fabry Disease12
Frequently asked questions about Shire
- How many clinical trials does Shire have on ClinicalTrials.gov?
- Shire is listed as the lead sponsor on 353 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Shire's trials are in Phase 3?
- 149 of Shire's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Shire focus on?
- Shire's most-studied conditions on ClinicalTrials.gov are Hereditary Angioedema (HAE), Healthy, Short Bowel Syndrome, Attention Deficit Hyperactivity Disorder (ADHD), Ulcerative Colitis.
- When are Shire's next clinical trial readouts?
- Shire has 1 upcoming primary-completion readout tracked here; the soonest is “A Study of Replagal in Children and Adults With Fabry Disease in India”, expected around 2026-10-31.